Pulmatrix appoints Robert Clarke as CEO

Thursday, September 6, 2012 08:28 AM

Pulmatrix, a Lexington, Mass.-based clinical stage biotechnology company, has promoted Robert Clarke, Ph.D., to the position of CEO and to the board of directors.

Previously, Clarke served as Pulmatrix’s chief scientific officer and vice president of R&D. Joining Pulmatrix in 2004, he has helped develop Pulmatrix technologies, iCALM and iSPERSE, for treatment of respiratory disease. Previous to Pulmatrix, Clarke was an associate director of life sciences at Alkermes, focused mainly on developing inhaled therapeutic products with the AIR technology platform.

Clarke has over 12 years of industry experience and over 20 years total experience focused on pulmonary drug delivery and the role of inhaled particles in respiratory biology and medicine, leading to co-authorship of over 80 chapters, papers and abstracts.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

April 21

Healthcare IPOs soar in first quarter

Survey compares 'push/pull' tactics in patient recruitment

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

April

Make way for mobile health in clinical trials
Despite patient retention, data quality benefits, regulatory hurdles persist

Global clinical trial laboratories decentralize
Regional labs reducing complexity, delivering cost and time savings

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

March

Strategic alliances hit bumps in the road
Mixed relationship performance driving new approaches

Tapping community hospitals for clinical trial volunteers
New study finds high potential but infrastructure, resources are lacking

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs